News

Innodem Neurosciences received $6 million to advance its digital biomarker eye-tracking technology as a possible way of diagnosing and monitoring neurodegenerative diseases. The technology is now being tested in people with multiple sclerosis (MS). Money raised by the Montreal-based startup came through a series A financing round led by Morningside Ventures.

People with primary progressive MS (PPMS) appeared to show a much stronger response and to be the” driving” force behind a slowing in brain atrophy seen with ibudilast treatment in the SPRINT‐MS trial, a post-hoc study analysis reports. The treatment response observed in brain atrophy was more evident…

A stem cell transplant can prevent disability progression and maintain disease remission over long periods of time in most patients with relapsing forms of multiple sclerosis (MS) who failed to respond adequately to disease-modifying therapies (DMTs), a study reports. The study, “Long-Term Clinical Outcomes of Hematopoietic…

The National Institute for Health and Care Excellence (NICE) does not recommend Zeposia (ozanimod) be available at low or no cost through the National Health Service (NHS) to treat adults with active relapsing-remitting multiple sclerosis (RRMS) living in England and Wales. In a recent draft recommendation, NICE stated that …

The upcoming Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) 2021 Forum will focus on the spectrums of multiple sclerosis (MS), related inflammation, disease severity, and the latest findings in the field. According to an ACTRIMS press release, about 1,000 researchers and clinicians are expected to…

People with primary progressive multiple sclerosis (PPMS) have significantly higher levels of a nerve injury-induced protein, called SERPINA3, in the cerebrospinal fluid (CSF) than do those with relapsing-remitting MS (RRMS) and those without the neurodegenerative disease, a study shows. Of note, the CSF is the liquid that bathes…

Oleic acid, a type of fatty acid, is important for the function of immune cells that are dysregulated in multiple sclerosis (MS), an early study shows. A diet rich in oleic acid may potentially be beneficial for these patients, although researchers emphasized the need for more studies. The study,…

Researchers from the Kessler Foundation will launch a new study investigating the effects of Tysabri (natalizumab) on cognitive fatigue — the type of fatigue that happens after strong mental concentration, such as in problem-solving — in people with relapsing-remitting multiple sclerosis (RRMS). Cognitive fatigue, which is very…

A new primate model uncovered by researchers can help scientists understand the immune and inflammatory processes underlying the development of multiple sclerosis (MS) in humans, a study reports. It was already known that Japanese macaques — also called snow monkeys — can spontaneously develop encephalomyelitis (JME), a disorder that…

Clene Nanomedicine has been notified it will be given a U.S. patent, as requested, covering an invention using the company’s already patented gold nanocrystals for the treatment of multiple sclerosis (MS). A Notice of Allowance was received by the company. These notices are issued by the U.S. Patent…

Changes in the amount of grey matter in specific regions of the brain appear to occur early in relapsing multiple sclerosis (MS), while structural changes in white matter happen late in disease progression. These were among the findings of a recent study that tracked the sequence of events in…

In addition to significantly reducing subsets of B-cells — its main immune cell target — Ocrevus (ocrelizumab) lessens pro-inflammatory immune T-cells in people with primary progressive multiple sclerosis (PPMS), a small study shows. Notably, the suppression of immune cell subsets thought to be involved in the abnormal immune responses…

Tonix Pharmaceuticals has filed a patent application with the World Intellectual Property Organization covering the use of TNX-1500 — its third-generation anti-CD154 antibody — for the prevention and treatment of autoimmune diseases, such as multiple sclerosis (MS), and organ transplant rejection. “There remains a significant need for new treatments with improved…

A thyroid hormone-mimicking compound not only prevented nerve cell damage but promoted the cells’ survival in a mouse model of multiple sclerosis (MS). This discovery advances previous research showing that the compound, called sobetirome, can induce the repair of myelin, the protective sheath around nerves. The data suggest…

Silo Pharma has entered into a sponsored research agreement with the University of Maryland to develop and explore the potential of a targeted therapy delivery system for multiple sclerosis (MS). The company and investigators at the Baltimore university will test a targeted therapy delivery approach that…

Sexual dysfunction affects more than 60% of adult men with multiple sclerosis (MS), according to a review study. The data add to previous findings showing that more than two-thirds of women with MS also experience these problems, highlighting the importance of detecting and managing sexual dysfunction in…

Scientists at the UCLA Broad Stem Cell Research Center have developed a technique able to more efficiently isolate specific T-cells — immune cells involved not only in the fight against infections and cancer but also in autoimmune diseases such as multiple sclerosis (MS) — for research. In particular, the…

Open Book Extracts (OBX) and Case Western Reserve University School of Medicine have partnered to investigate how cannabinoids like CBD affect brain cells, particularly in regard to neuroinflammation, according to an OBX press release. CBD (cannabidiol) and other cannabinoids, such as THC (tetrahydrocannabinol), have attracted interest for…

Scientists have discovered epigenetic changes in a gene called HTR2A, found only in immune cells isolated from people with secondary progressive multiple sclerosis (SPMS), a study reported.  These findings suggest that such changes — external modifications to DNA that turn genes…

GW Pharmaceuticals is planning to continue recruiting patients into two pivotal Phase 3 clinical trials of Sativex (nabiximols), an oral spray that contains cannabis extracts and is being investigated as a potential add-on therapy for people with multiple sclerosis (MS) and spasticity. The company also is…

Lemtrada (alemtuzumab) may slow the progression of multiple sclerosis (MS) and lower the conversion rate of relapsing-remitting MS (RRMS) to secondary progressive MS (SPMS), a long-term study suggests. The results showed that patients converting to SPMS — in which a person’s disability gets steadily worse — were older,…

Helius Medical Technologies has submitted its response to the U.S. Food and Drug Administration (FDA)’s request for more information about the company’s application for de novo classification and clearance of its portable neuromodulation stimulator (PoNS) device to help treat walking difficulties in people…

Imatinib, a cancer treatment, stopped an injury response mechanism of the central nervous system (CNS) from activating, damage to which is a hallmark of multiple sclerosis (MS), an early study reported. Treatment with imatinib lessened immune cell infiltration and eased disease progression in mouse models of MS. Study researchers…

BioNTech’s experimental non-inflammatory vaccine — designed to dampen the abnormal immune responses seen in multiple sclerosis (MS) against myelin — delayed the onset and lessened the severity of symptoms in a mouse model of MS, a study reports. Importantly, treated mice showed no signs of overall immune suppression,…

Long-term use of disease-modifying therapies (DMTs) in people with relapsing-remitting multiple sclerosis (RRMS) has a beneficial cumulative effect compared to shorter treatments, delaying the development of irreversible disability and conversion to secondary progressive MS (SPMS), a recent study…

To fully understand autoimmune diseases like multiple sclerosis (MS), it is necessary to study not just the immune system, but also the tissue that the immune system is attacking, a study suggests. “We must move away from the present ‘immune-centric-only’ view of autoimmune diseases,” Decio Eizirik, MD, PhD, study…

CXCL13, an inflammatory biomarker, may be a good marker of likely future disease activity in people with multiple sclerosis (MS), a study suggests. The study, “Intrathecally produced CXCL13: A predictive biomarker in multiple sclerosis,” was published in the Multiple Sclerosis Journal – Experimental, Translational and Clinical. Clinicians caring…

Desi Harrison, a multiple sclerosis (MS) patient and president of the nonprofit MS Warriors for a Cause, has donated $700,000 to support the Ochsner Neuroscience Institute. The funds will help support research and care at the Ochsner Multiple Sclerosis Center to ensure that patients — like Harrison, who…

Obesity and a higher body mass index (BMI) are associated with both increased multiple sclerosis (MS) risk and harmful autoimmune activity that is induced by leptin, a hormone secreted by fat cells, a study finds. These results indicate that leptin, which helps regulate…

Reduced exposure to sunlight, previously reported as a risk factor for developing multiple sclerosis (MS), also seems to increase the risk for relapse and worsening disability, data from two clinical studies suggest. The beneficial effects of sunlight exposure were linked to increased levels of vitamin D, but also modulation…